CR20150153A - Tratamiento para artitris reumatoide - Google Patents

Tratamiento para artitris reumatoide

Info

Publication number
CR20150153A
CR20150153A CR20150153A CR20150153A CR20150153A CR 20150153 A CR20150153 A CR 20150153A CR 20150153 A CR20150153 A CR 20150153A CR 20150153 A CR20150153 A CR 20150153A CR 20150153 A CR20150153 A CR 20150153A
Authority
CR
Costa Rica
Prior art keywords
treatment
artitris
reumatoid
rheumatoid arthritis
csf antibodies
Prior art date
Application number
CR20150153A
Other languages
English (en)
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Janssen Pharmaceutica Nv
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Morphosys Ag filed Critical Janssen Pharmaceutica Nv
Publication of CR20150153A publication Critical patent/CR20150153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos anti-GM-CSFpara utilizarse en el tratamiento de artritis reumatoide. Losanticuerpos anti-GM-CSF, en particular MOR103, se administran alos pacientes que padezcan de artritis reumatoide en dosificaciones que sean benéficas en una situación clínica
CR20150153A 2012-09-20 2015-03-20 Tratamiento para artitris reumatoide CR20150153A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21
PCT/EP2013/069501 WO2014044768A1 (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CR20150153A true CR20150153A (es) 2015-09-14

Family

ID=46963526

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150153A CR20150153A (es) 2012-09-20 2015-03-20 Tratamiento para artitris reumatoide

Country Status (23)

Country Link
US (3) US20150246969A1 (es)
EP (3) EP3345923A1 (es)
JP (3) JP2015533806A (es)
KR (3) KR20230041086A (es)
CN (2) CN104995210A (es)
AU (2) AU2013320261A1 (es)
BR (1) BR112015006189B1 (es)
CA (1) CA2884124A1 (es)
CL (2) CL2015000696A1 (es)
CR (1) CR20150153A (es)
DO (1) DOP2015000070A (es)
EA (1) EA031489B1 (es)
HK (1) HK1208231A1 (es)
IL (1) IL237554B (es)
IN (1) IN2015KN00657A (es)
MA (1) MA37946B1 (es)
MX (2) MX2015003644A (es)
MY (1) MY175388A (es)
PE (1) PE20151079A1 (es)
PH (1) PH12015500591A1 (es)
SG (2) SG10201803778PA (es)
UA (1) UA117228C2 (es)
WO (1) WO2014044768A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201803778PA (en) * 2012-09-20 2018-06-28 Morphosys Ag Treatment for rheumatoid arthritis
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
MX2016002177A (es) 2013-08-30 2016-06-28 Takeda Gmbh Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
WO2015138638A1 (en) * 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
EP3389696A4 (en) 2015-12-17 2019-08-14 The Johns Hopkins University TREATING SYSTEMIC SCLEROSIS WITH DEATH RECEPTOR AGONISTS
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
AU2017328383B2 (en) * 2016-09-19 2022-10-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Anti-GM-CSF antibodies and uses thereof
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP2001501619A (ja) 1996-10-04 2001-02-06 アムジェン インコーポレーテッド ｍｐｌリガンドを含有する医薬組成物
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
BRPI0610796B8 (pt) * 2005-05-18 2021-05-25 Morphosys Ag anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
WO2007037795A2 (en) 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US8093360B2 (en) * 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
ES2432173T3 (es) * 2006-11-21 2013-12-02 Kalobios Pharmaceuticals, Inc. Métodos de tratamiento de enfermedades inflamatorias crónicas usando un antagonista de GM-CSF
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
AU2008232506A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to B-cell antagonists
US9119789B2 (en) 2007-04-05 2015-09-01 Sandoz Ag Stable aqueous G-CSF formulations
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CA2705539A1 (en) 2007-11-13 2009-05-22 Evec Inc. Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010071923A1 (en) * 2008-12-22 2010-07-01 The University Of Melbourne Pain treatment
ES2886063T3 (es) 2008-12-22 2021-12-16 Univ Melbourne Tratamiento de la artrosis
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
BRPI1006514A2 (pt) * 2009-05-05 2019-01-08 Morphosys Ag antagonista do gm-csf
SI2341061T1 (sl) 2009-12-31 2013-12-31 Arven Ilac Sanayi Ve Ticaret A.S. Nov postopek za pripravo G-CSF-ja (granulocitne kolonije stimulirajočega faktorja)
CN105521491B (zh) * 2010-03-01 2020-03-24 西托戴恩有限公司 浓缩蛋白制剂及其用途
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
SG10201803778PA (en) * 2012-09-20 2018-06-28 Morphosys Ag Treatment for rheumatoid arthritis

Also Published As

Publication number Publication date
CN109999195A (zh) 2019-07-12
CA2884124A1 (en) 2014-03-27
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
KR20150056846A (ko) 2015-05-27
EP2897977A1 (en) 2015-07-29
EP3345923A1 (en) 2018-07-11
HK1208231A1 (en) 2016-02-26
EA201590359A1 (ru) 2015-08-31
IN2015KN00657A (es) 2015-07-17
AU2016250388A1 (en) 2016-11-17
IL237554B (en) 2019-12-31
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (en) 2014-03-27
US20150246969A1 (en) 2015-09-03
MX2021006111A (es) 2021-07-07
MA37946B1 (fr) 2018-09-28
JP2022169709A (ja) 2022-11-09
EP3916013A1 (en) 2021-12-01
BR112015006189A2 (pt) 2019-11-26
US20180230208A1 (en) 2018-08-16
CL2015000696A1 (es) 2015-10-23
KR20220028177A (ko) 2022-03-08
SG10201803778PA (en) 2018-06-28
MA37946A1 (fr) 2018-01-31
JP2015533806A (ja) 2015-11-26
AU2016250388B2 (en) 2018-07-19
PH12015500591B1 (en) 2015-05-11
IL237554A0 (en) 2015-04-30
JP2018138551A (ja) 2018-09-06
PE20151079A1 (es) 2015-08-07
UA117228C2 (uk) 2018-07-10
PH12015500591A1 (en) 2015-05-11
EA031489B1 (ru) 2019-01-31
CL2018000933A1 (es) 2018-07-20
MX2015003644A (es) 2015-09-25
BR112015006189B1 (pt) 2022-04-05
US20210130451A1 (en) 2021-05-06
CN104995210A (zh) 2015-10-21
US10913792B2 (en) 2021-02-09
AU2013320261A1 (en) 2015-04-09
DOP2015000070A (es) 2015-08-16

Similar Documents

Publication Publication Date Title
CR20150153A (es) Tratamiento para artitris reumatoide
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
TN2015000396A1 (en) Antibody drug conjugates
MA34091B1 (fr) Anticorps anti-cd40
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
PE20150002A1 (es) Anticuerpos anti-fcrn
UA113403C2 (xx) Спосіб підвищення ефективності folr1 терапії раку
EA201400178A1 (ru) Лечение рака молочной железы
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
EA201401204A1 (ru) Антитела к il-23p19
EA201590412A1 (ru) Композиции антител и их применения
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
NZ743656A (en) Methods of treating a tauopathy
TH137287B (th) สารชักนำอะพอพโทซิสสำหรับการรักษามะเร็งและโรคทางภูมิคุ้มกันและภูมิต้าน ตนเอง (Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases)